AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...

AbbVie has made another bolt-on deal in the ... Activation of the receptor reprogrammes the cells into less inflammatory behaviour and could have potential as a therapeutic strategy for chronic ...

Two medications manufactured by AbbVie, Vraylar and Linzess, are among 15 new drugs selected for the federal government’s new price negotiation program. Vraylar, which North Chicago-based AbbVie ...

AbbVie has filed with the FDA to extend the ... limited to people with depression as well as suicidal ideation and behaviour. Spravato was held up as a potential blockbuster at one point, but ...